XML 120 R43.htm IDEA: XBRL DOCUMENT v3.25.3
Commitments and Contingencies (Details Narrative) - USD ($)
Mar. 19, 2022
Sep. 30, 2025
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Commitments and Contingencies  
License Agreement [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Loss contingency allegations In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. If not terminated under terms of the agreement, the Equivir License expires the later of a) expiration date of the last to expire valid claim comprising the licensed patents, or (b) twelve (12) years from the date of first commercial sale. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $1,250,000. As of September 30, 2025 and December 31, 2024, a liability of $0 has been recorded in relation to the Equivir License.    
Sale of royalty percentage 5.50%    
Development cost, percent 50.00%    
Development costs $ 1,250,000    
Commitments and Contingencies   $ 0 $ 0